The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence
Therapeutic Advances in Vaccines · 2013
DOI: 10.1177/2051013613480446 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Vaccines, 2013. Verfasst von Emeline Ragonnaud und 1 weiteren Autor:innen. Beteiligte Einrichtung: ISIM - Center for Medical Parasitology, Copenhagen, Denmark. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The development of vaccines that target tumor antigens in cancer has proven difficult. A major reason for this is that T cells specific for tumor self-antigens and neoantigens are eliminated or inactivated through mechanisms of tolerance. Antigen fusion strategies which increase the ability of vaccines to stimulate T cells that have escaped tolerance mechanisms, may have a particular potential as immunotherapies. This review highlights antigen fusion strategies that have been successful in stimulating the induction of T-cell immunity against cancer and counteracting tumor-associated tolerance. In preclinical studies, these strategies have shown to improve the potency of vectored vaccines through fusion of tumor antigen to proteins or protein domains that increase CD4+ T-cell help, CD8+ T-cell responses or both the CD4+ and CD8+ T-cell responses. However, in clinical trials such strategies seem to be less efficient when provided as a DNA vaccine. The first clinical trial using a viral vectored fusion-gene vaccine is expected to be tested as a partner in a heterologous prime-boost regimen directed against cervical cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- ISIM - Center for Medical Parasitology, Copenhagen, Denmark.
Zitieren
APA
Ragonnaud, E., & Holst, P. (2013). The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Therapeutic Advances in Vaccines. https://doi.org/10.1177/2051013613480446
Vancouver
Ragonnaud E, Holst P. The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Therapeutic Advances in Vaccines. 2013. doi:10.1177/2051013613480446
BibTeX
@article{Ragonnaud2013,
author = {Ragonnaud, Emeline and Holst, Peter},
title = {The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence},
journal = {Therapeutic Advances in Vaccines},
year = {2013},
doi = {10.1177/2051013613480446}
}
EUVIMED